BPC-157 has an unusually large preclinical literature and an unusually small clinical one, and the gap between those two facts is the most important thing to understand about the molecule in 2026. Hundreds of published animal and cell studies exist; published randomised human trials essentially do not. Neither observation cancels the other, but conflating them is how most summaries go wrong.
What the molecule is
BPC-157 is a 15-residue synthetic peptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, catalogued at CAS 137525-51-0 with a molecular weight of 1,419.55 Da. It corresponds to a partial sequence of a larger protein described in human gastric juice, from which it takes the name "body protection compound". Structurally it is unremarkable — linear, no disulfides, no methionine, proline-rich — and that proline content is part of why it is described in the literature as comparatively resistant to gastric degradation. Full structural detail is in what is BPC-157, and the naming is defined at gastric pentadecapeptide.
Two salt forms circulate in research supply. The acetate form is standard; an arginate form is described as more stable in aqueous conditions, which is the rationale behind oral research formats such as BPC-157 arginate capsules.
What has been studied
The published work clusters into recognisable groups, almost all rodent or in vitro.
| Research area | Model type | Reported focus |
|---|---|---|
| Tendon and ligament | Rat transection models; isolated tendon fibroblasts | Fibroblast outgrowth and migration; FAK–paxillin pathway activation in vitro |
| Gastrointestinal | Rodent colitis (DSS, TNBS), NSAID-induced gastric lesion, fistula models | Mucosal integrity endpoints and lesion scoring |
| Muscle | Rat crush and transection injury | Functional recovery and histological endpoints |
| Vascular | Rodent ischaemia and vessel models | Angiogenic signalling, VEGFR2 and nitric-oxide system involvement |
| Nervous system | Rat nerve crush, spinal cord and encephalopathy models | Functional recovery scoring |
| Systemic and counteracting effects | Rodent models of drug and toxin exposure | Reported attenuation of induced lesions |
The mechanistic thread most often proposed connects angiogenic signalling — VEGFR2 activation with downstream Akt and eNOS involvement — to the tissue endpoints seen across models. That is a coherent hypothesis and it is supported by in vitro work; it is not the same as an established mechanism in a mammal, and the literature itself is generally careful about that. Vocabulary at angiogenesis.
What has not been studied
Four gaps are worth naming precisely.
Randomised human trials. There is no substantial published randomised controlled human dataset for BPC-157 in any indication. A related pharmaceutical development programme under earlier code names explored inflammatory bowel disease, but the results were not published as a full peer-reviewed clinical dataset and the programme did not continue to registration. Any article implying human efficacy evidence is over-reading.
Human pharmacokinetics. Absorption, distribution, metabolism and elimination in people are not characterised in the published record. Half-life figures circulating online are extrapolations, not measurements.
Independent replication breadth. A large fraction of the preclinical corpus originates from one research group and its collaborators. That is not an accusation of error — it is a description of the evidence structure, and it means the literature has less independent replication than its raw volume suggests. Genuine independent replication of the headline tendon and gastrointestinal findings would materially change confidence.
Long-term exposure. Chronic administration data, carcinogenicity assessment and reproductive toxicology are absent from the public record in the depth a regulatory dossier would require. Angiogenic signalling in particular is a mechanism where long-term consequences are a legitimate open question rather than a rhetorical one.
Formats and what they change
A second, quieter research question concerns format rather than molecule. Injectable lyophilised vials, oral capsules, sublingual troches, nasal sprays and topical creams all appear in the catalogue, and each implies a different exposure assumption. Oral formats raise the bioavailability question directly: a 15-residue peptide entering the gastrointestinal tract encounters peptidases even if its proline content confers relative resistance, and the published rodent work that used oral administration typically delivered the peptide in drinking water over extended periods rather than as a discrete unit. Topical and nasal formats bypass that entirely but introduce their own delivery variables. When comparing published results, the administration route is not a minor methodological footnote — it frequently determines whether two studies are measuring comparable exposure at all.
Where the regulatory position stands
BPC-157 has no marketing authorisation in the United States or the European Union. It was placed on the FDA's list of bulk substances not eligible for compounding under the relevant category following review, which effectively closed the compounding-pharmacy route. It is also listed by the World Anti-Doping Agency, which matters for any research involving competitive athletes. Research-grade material is supplied strictly for laboratory use; nothing in the preclinical literature transfers to a lyophilised research vial as an authorisation. Context in what research use only means.
Reading the literature well
Three habits improve interpretation. First, check the model: a rat tendon transection is a severe, acute, standardised injury, and translation from it is a genuine scientific problem rather than a formality. Second, check the route and comparator: many rodent studies use intraperitoneal or in-drinking-water administration, neither of which maps onto other formats. Third, check who ran it, because concentration of a literature in one group changes how much weight independent confirmation should carry.
For laboratory work, the practical specifications are straightforward. BPC-157 research vials are supplied at 5–20 mg; use 1,419.55 Da for molar calculations. Oral research formats include BPC-157 capsules, and the most-studied comparison in the tissue-repair space is set out in BPC-157 vs TB-500. The wider category sits in tissue repair peptides, with class context in the joints and tendons research overview.
The honest summary
BPC-157 is one of the most-studied research peptides in rodents and one of the least-studied in people. It has a plausible proposed mechanism, a consistent preclinical signal across several injury models, no clinical evidence base, no pharmacokinetic characterisation in humans, and a regulatory position that reflects all of that. State it that way and you will be more accurate than most of what is written about it.